Drug Trial Radar · NCT04747964
A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jan 15, 2020
Primary completion
Apr 19, 2021
Study completion Apr 19, 2021
Sponsor
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the pharmacokinetics and pharmacodynamics of STSP-0601 at six dose levels. The results will help identify the most optimal doses to treat bleedings in hemophilia patients with inhibitors.
Conditions
- Hemophilia
Interventions
STSP-0601 for InjectionDrug
Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements
STSP-0601 for InjectionDrug
Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements
STSP-0601 for InjectionDrug
Subjects will receive one single low-intermediate dose of STSP-0601 for Injection following protocol requirements
STSP-0601 for InjectionDrug
Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements
STSP-0601 for InjectionDrug
Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements
STSP-0601 for InjectionDrug
Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects of adverse eventsTime frame: Baseline to Day 8
- Number of subjects With Significant Abnormal Physical ExaminationTime frame: Baseline to Day 8
- Number of subjects of Significant Abnormal Vital Signs FindingsTime frame: Baseline to Day 8
- Number of Participants With Significant Abnormal Laboratory ValuesTime frame: Baseline to Day 8
- Number of subjects With Significant Abnormal Electrocardiography (ECG) FindingsTime frame: Baseline,1 hour,4 hour,48 hour,Day 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.